IN Brief:
- FSA and FSS have published two further pieces of guidance through the Cell-Cultivated Products Sandbox Programme.
- The documents cover the regulated products framework plus assessment of growth media components and toxicological hazards.
- The guidance is intended to improve dossier quality and clarify the evidence expected when seeking Great Britain market authorisation.
The Food Standards Agency and Food Standards Scotland have published two further pieces of guidance for cell-cultivated food developers, adding detailed advice on market authorisation, growth media, and toxicological assessment.
The documents form the latest output from the Cell-Cultivated Products Sandbox Programme, which has been running since February 2025 and is due to conclude in February 2027. The programme is intended to turn experience gained through engagement with developers into practical supplementary guidance for businesses preparing products for regulatory assessment.
One publication explains how the Great Britain regulated products framework applies to cell-cultivated products. The second focuses specifically on assessing growth media components and toxicological hazards when applicants prepare a safety dossier.
Most cell-cultivated foods seeking entry to the Great Britain market are expected to require novel food authorisation. That process requires scientific and technical information sufficient for regulators to assess whether the proposed product is safe under its intended conditions of use before a decision can be made on authorisation.
The new documents do not alter that underlying legal framework. Their role is to give companies a clearer view of how existing requirements apply to cell-cultivated production and which evidence regulators expect to see in a sufficiently complete application.
That distinction matters to developers because the production system is unusually complex. A cell-cultivated food dossier may need to describe the origin and identity of the cells, culture conditions, production stages, growth media, harvesting, downstream processing, final composition, microbiological controls, and the intended use of the finished product.
The latest toxicology and growth media guidance concentrates on substances introduced during cell growth and production. Growth media can contain amino acids, vitamins, minerals, growth factors, hormones, antimicrobials, surfactants, antifoams, pH regulators, and other materials used to keep cells viable and productive.
Applicants need to consider whether those substances remain in the harvested material or finished food, whether biologically active compounds persist at relevant concentrations, and whether analytical evidence is required to demonstrate removal or establish residual levels.
That brings process engineering directly into the regulatory evidence. Washing, harvesting, separation, purification, media exchange, and other downstream operations do not simply affect yield and manufacturing cost; they can determine what compounds remain in the final product and therefore what analytical work is required to support a safety assessment.
Scaffolds and microcarriers create a similar issue. Materials used to support cell growth may remain in the product or be removed before consumption. Their regulatory treatment consequently depends on composition, function, residual presence, and the way they are handled during processing.
The guidance should also help companies identify evidence gaps before a dossier reaches formal assessment. Requests for further information can add significant time to regulated product applications where a submission does not sufficiently explain production, composition, analytical methods, or toxicological considerations.
Earlier Cell-Cultivated Products Sandbox work showed reductions in initial information-request times, while identifying application quality as an important influence on assessment efficiency. The latest guidance addresses that problem from the other direction by giving developers more detail about the information regulators expect before an application is submitted.
The publications follow an earlier package issued in July covering areas including product identity, production, microbiology, hygiene, and preparation of stronger applications. The latest documents extend that guidance into two areas that can become particularly complicated as a laboratory process begins to resemble commercial manufacturing.
Growth media that works economically at research scale may be altered during scale-up, while equipment, process conditions, and downstream operations can also change as developers try to increase productivity. Those changes have to be documented sufficiently for regulators to understand the product actually intended for market rather than an earlier laboratory version of it.
For manufacturers, this places regulatory planning alongside process development. Decisions about media composition, raw material specifications, cleaning, harvesting, analytical methods, and production controls influence both factory performance and the evidence needed to support an application.
The new documents will not make a weak safety dossier strong by themselves, nor do they remove the scientific assessment required before authorisation. Their practical value is narrower and more useful: developers now have more specific information about what regulators are likely to ask and can design production, testing, and documentation around those expectations earlier.
For a sector still moving from pilot equipment towards commercial plants, avoiding regulatory surprises after major process decisions have already been fixed is likely to be considerably cheaper than redesigning the evidence package afterwards.